Hong Kong's three major stock indices all closed in negative territory on Monday.
The benchmark Hang Seng Index fell 1.56% to finish at 25,633.21 points.
The Hang Seng Tech Index declined by 2.74%, while the Hang Seng China Enterprises Index dropped 1.9%.
Market Sector Performance
Technology and internet stocks were broadly lower.
Meituan (HKEX: 3690) shares fell over 5%, with JD.com (HKEX: 9618) and Kuaishou (HKEX: 1024) both down more than 4%.
Bilibili (HKEX: 9626), Alibaba Group (HKEX: 9988), Xiaomi Corp (HKEX: 1810), and Tencent Holdings (HKEX: 700) all saw declines exceeding 3%.
Standout Performers
In contrast, the optical communications sector bucked the downtrend.
Yangtze Optical Fibre and Cable Joint Stock Limited Company (HKEX: 6869) surged more than 10%.
Other Notable Moves
Innovative drug concept stocks weakened, with WuXi Biologics (Cayman) Inc. (HKEX: 2269) dropping 7%.
Airline stocks collectively pulled back, with China Eastern Airlines Corporation Limited (HKEX: 0670) falling over 5%.
New listing Shougang LanzaTech (HKEX: 6960) jumped more than 44% on its first day of trading.
Focus on Optical Communications
The sector's strength followed news of a significant technological breakthrough.
A new S+C+L triple-band ultra-low loss multi-core optical cable line, jointly designed by Hengtong Optic-Electric Co., Ltd and China Mobile, was launched in Qingdao, Shandong.
This line offers a single-fiber capacity over five times that of traditional cables, providing a new solution for AI computing interconnectivity.
Sentiment was also lifted by overnight gains in US-listed optical communications chip leader Marvell Technology, Inc. (NASDAQ: MRVL), whose shares soared over 32%.
Its CEO, Matt Murphy, stated that data center connectivity is becoming the next major bottleneck for AI growth.
NVIDIA CEO Jensen Huang publicly remarked that Marvell "will be the next trillion-dollar company."
Innovative Drug Sector Commentary
An analysis report highlighted a continued positive outlook for the sector's three main themes through 2026: innovation, overseas expansion, and recovery/strategic transformation.
For pharmaceutical innovation, the report suggested a foundational portfolio of large pharmaceutical firms, biotechs already expanding overseas, and supply chain companies.
It recommended seeking alpha in new technological areas like small nucleic acids and AI-driven drug discovery.
For medical devices, the focus was on the overseas expansion theme and emerging areas like brain-computer interfaces and robotics.
Airline Sector Analysis
The pullback in airline stocks occurred alongside rising crude oil prices, driven by heightened market concerns over escalating tensions in the Middle East.
A research view maintains that while high oil prices present a short-term operational headwind, they do not alter the medium-to-long-term logic of improving industry supply and demand.
The strong first-quarter earnings for airlines in 2026 have preliminarily validated profitability under these improving conditions, supporting a positive outlook for a sector recovery from its cyclical low.
New Listing Details
During its public offering, Shougang LanzaTech's shares were oversubscribed by approximately 1,421.54 times.
After reallocation, the final number of shares offered to the public was 6 million, representing about 15% of the total offering.
The company received roughly 109,100 valid applications, with about 21,872 applications processed.
The probability of an allottee receiving one board lot was approximately 2%.
In the international placement segment, the shares were 0.95 times subscribed, with the final number of international offering shares set at 34 million, equivalent to 85% of the total offering.
Comments